Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Research & Development (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Research & Development data on record, last reported at $3.7 million in Q3 2025.

  • For Q3 2025, Research & Development fell 24.21% year-over-year to $3.7 million; the TTM value through Sep 2025 reached $15.2 million, down 23.5%, while the annual FY2024 figure was $17.7 million, 9.02% down from the prior year.
  • Research & Development reached $3.7 million in Q3 2025 per MBRX's latest filing, up from $3.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $6.6 million in Q4 2023 and bottomed at $3.0 million in Q2 2021.
  • Average Research & Development over 5 years is $4.3 million, with a median of $4.1 million recorded in 2021.
  • Peak YoY movement for Research & Development: skyrocketed 77.94% in 2021, then plummeted 45.01% in 2023.
  • A 5-year view of Research & Development shows it stood at $3.2 million in 2021, then skyrocketed by 31.47% to $4.2 million in 2022, then skyrocketed by 58.74% to $6.6 million in 2023, then crashed by 32.83% to $4.5 million in 2024, then decreased by 16.09% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $3.7 million in Q3 2025, $3.6 million in Q2 2025, and $3.4 million in Q1 2025.